JP2022183183A5 - - Google Patents

Download PDF

Info

Publication number
JP2022183183A5
JP2022183183A5 JP2022152791A JP2022152791A JP2022183183A5 JP 2022183183 A5 JP2022183183 A5 JP 2022183183A5 JP 2022152791 A JP2022152791 A JP 2022152791A JP 2022152791 A JP2022152791 A JP 2022152791A JP 2022183183 A5 JP2022183183 A5 JP 2022183183A5
Authority
JP
Japan
Prior art keywords
treatment
composition
vegf
patient
wamd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022152791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022183183A (ja
Filing date
Publication date
Priority claimed from PCT/CN2014/093548 external-priority patent/WO2016090590A1/en
Priority claimed from JP2020173951A external-priority patent/JP2021004262A/ja
Application filed filed Critical
Publication of JP2022183183A publication Critical patent/JP2022183183A/ja
Publication of JP2022183183A5 publication Critical patent/JP2022183183A5/ja
Pending legal-status Critical Current

Links

JP2022152791A 2014-12-11 2022-09-26 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 Pending JP2022183183A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2014/093548 WO2016090590A1 (en) 2014-12-11 2014-12-11 Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion
CNPCT/CN2014/093548 2014-12-11
CN2015089251 2015-09-09
CNPCT/CN2015/089251 2015-09-09
JP2020173951A JP2021004262A (ja) 2014-12-11 2020-10-15 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020173951A Division JP2021004262A (ja) 2014-12-11 2020-10-15 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療

Publications (2)

Publication Number Publication Date
JP2022183183A JP2022183183A (ja) 2022-12-08
JP2022183183A5 true JP2022183183A5 (https=) 2023-09-27

Family

ID=55069121

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017530277A Active JP7320919B2 (ja) 2014-12-11 2015-12-10 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療
JP2020173951A Pending JP2021004262A (ja) 2014-12-11 2020-10-15 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療
JP2022152791A Pending JP2022183183A (ja) 2014-12-11 2022-09-26 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017530277A Active JP7320919B2 (ja) 2014-12-11 2015-12-10 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療
JP2020173951A Pending JP2021004262A (ja) 2014-12-11 2020-10-15 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療

Country Status (16)

Country Link
US (2) US20170326106A1 (https=)
EP (2) EP3985023A1 (https=)
JP (3) JP7320919B2 (https=)
CN (3) CN114306575A (https=)
AU (4) AU2015360496B2 (https=)
CA (1) CA2970315C (https=)
DK (1) DK3230316T3 (https=)
ES (1) ES2907148T3 (https=)
HR (1) HRP20220066T1 (https=)
HU (1) HUE057653T2 (https=)
LT (1) LT3230316T (https=)
PL (1) PL3230316T3 (https=)
PT (1) PT3230316T (https=)
RS (1) RS62827B1 (https=)
SI (1) SI3230316T1 (https=)
WO (1) WO2016094673A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
US10525035B2 (en) * 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体
EP3873519A1 (en) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antibody formulation
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025047970A1 (ja) * 2023-08-31 2025-03-06 国立大学法人京都大学 光感受性物質含有リポタンパク質、光線力学的療法用製剤、薬物デリバリー方法及び後眼部新生血管閉塞方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69735292T2 (de) 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗vegf抗体
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US8034803B2 (en) * 2001-02-06 2011-10-11 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20260004598A (ko) * 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa

Similar Documents

Publication Publication Date Title
JP2022183183A5 (https=)
AU2021245214B2 (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
JP2025169389A5 (https=)
Faghihi et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema
Cukras et al. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study
JP2017061467A5 (https=)
CN1582156A (zh) 眼新血管疾病的治疗方法
CA3025258C (en) Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
JP5934229B2 (ja) 眼血管疾患の処置のための投与計画
JP7828274B2 (ja) 眼疾患を治療するための方法
Kang et al. The efficacy of ranibizumab for choroidal neovascularization in age-related macular degeneration
Querques et al. Intravitreal ranibizumab for choroidal neovascularization associated with retinal astrocytic hamartoma
KR20160013026A (ko) 폴립양 맥락막 혈관병증의 치료
HK40071471A (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
HK40051590A (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
Bennet Pegaptanib for the treatment of ischemic retinopathy in patients with diabetes and retinal vascular occlusive disorders
TW202525324A (zh) 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法
Sinha et al. Anti-vascular endothelial growth factor in ophthalmology
WO2024153184A1 (zh) 一种使用抗vegf抗体治疗眼底血管病变的方法
Jong et al. Intravitreal triamcinolone versus bevacizumab for treatment of diabetic macular edema
HK1239535A1 (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
Mahar et al. Visual Outcome Following Intra-vitreal Bevacizumab Injection in Neovascular Age-related Macular Degeneration
Wong et al. Vitreous, Choroid, and Retina
OPTHALMOLOGY A MULTIVARIATE ANALYSIS OF INTRA VITREAL INJECTION OF ANTI VEGF BEVACIZUMAB IN THE TREATMENT OF RETINAL AND CHOROIDAL NEOVASCULARISATION
WO2016090590A1 (en) Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion